Background {#Sec1}
==========

Different tools have been used to uncover biomarkers for the prediction of diabetes with and without complications. Determination of advanced glycation end product (AGE) which is usually associated with poor control of hyperglycemia has been used to predict diabetes with complications \[[@CR1]\]. Personalized tracing fasting and postprandial blood sugar or glycosylated hemoglobin A (HbA1c) have long been used to reflect blood glucose control and predict prognosis of T2DM \[[@CR2]\]. However, some HbA1c assays' capability to classify severity of diabetic patients is still unacceptable \[[@CR3]\]. Microalbuminuria has recently been significantly correlated with complications of T2DM \[[@CR4]\] and serum glucose levels were positively correlated with beta2-microglobulin and TNF-α levels \[[@CR5]\]. These findings suggest that, in addition to hyperglycemia, low levels of inflammatory and vascular insults may contribute to diabetic complications of nephropathy and/or retinopathy \[[@CR4], [@CR5]\]. Moreover, high levels of homocysteine have been associated with macrovascular and microvascular complications of T1DM, but not T2DM \[[@CR6]\], suggesting different types of diabetes and complications have different biomarkers.

Recently, proteomic approaches that identify biomarkers have been increasingly used to predict diabetes with different complications. Using ProteinChips assay, some peptides profiles in urine and blood have been referred to as biomarkers of T2DM \[[@CR7], [@CR8]\]. This solid-phase based mass spectrometry is usually displayed by profiles, but not specific or quantitative markers. There is also another liquid-phase bead-based proteomic approach used to differentiate T2DM patients from normal adults \[[@CR9]\]. Although these proteomic approaches are increasingly used to search for diabetic biomarkers in blood, no significant breakthroughs have been reported \[[@CR10]\]. This is usually limited by interference of high-abundance proteins in blood. We have previously defined T2DM with nephropathy by albumin excretion-creatinine ratio (AER) and analyzed prevalence and the risk factors for the complication \[[@CR11]\], and defined T2DM with retinopathy by photography and assessed the correlation of the retinopathy to cardiovascular autonomic scoring scale \[[@CR12]\]. In an attempt to identify unique biomarker(s) for the T2DM with nephropathy or retinopathy using the same cohort samples, we employed a proteomic display to compare low-abundance proteins of plasma samples between normal adults and T2DM patients, and sought to investigate whether T2DM patients with nephropathy or retinopathy had unique proteomic markers.

Methods {#Sec2}
=======

Study design and subjects studied {#Sec3}
---------------------------------

An age-matched case-control study design was initially used to screen proteomic differential profiles between diabetic patients and normal adults, followed by a quantitative validation of the inflammation-related differentially displayed proteins. The study was approved by the Institutional Review Board of the study hospital and informed consent was obtained from all participants. T2DM patients were recruited in the outpatient clinic of the study hospital, and normal adults who have a normal fasting blood sugar level were recruited from the Center for Health Examination of the study hospital. Plasma samples were collected in the morning with an overnight fasting condition and were harvested by ethylenediaminetetraacetate (EDTA) anticoagulant tubes. Comparison of the plasma proteomes between 8 pairs of age-matched T2DM patients and normal adults was performed by enrichment of low abundance proteins, followed by a gel-electrophoresis with in-gel digestion for nanoflow liquid chromatography electrospray ionization (nano LC-ESI) analyses and MetaCore analyses (Fig. [1](#Fig1){ref-type="fig"}). The different displays of plasma proteins were validated in another cohort of 149 T2DM patients with nephropathy or retinopathy and 30 normal adults as a control group. Normal adults were recruited from the Center for Health Examination of the study hospital who have a normal fasting blood sugar level \< 105 mg/dl, normal urine analysis and normal blood pressure at systolic BP \< 140 mmHg and diastolic BP \< 90 mmHg.Fig. 1Proteomic differential displays of plasma between normal adults and T2DM patients. **a** the low abundance proteins enriched by the multiple affinity removal of 14 high abundance proteins; **b** the low abundance proteins on the SDS-PAGE gels were incited into 16 pieces for in-gel digestion; **c** each fraction of in-gel digestion was subject to nano LC-ESI analyses of peptides fingerprints; and **d** proteins identified in all 8 plasma samples were analyzed by MetaCore analysis

Definition of T2DM with nephropathy or retinopathy {#Sec4}
--------------------------------------------------

Definition of T2DM with nephropathy was referred to albumin excretion-creatinine (AER) ratio in urine specimen. Albumin and creatinine concentrations were determined by nephelometry (Dade-Behring, Marburg, Germany), and nephropathy was defined as an AER exceeding 0.3 mg/mg in two urine samples collected within a 3- to 6-month period as our previously described \[[@CR11]\]. Definition of retinopathy was determined through fundus photography, equivalent to the scale of Early Treatment of Diabetic Retinopathy Study \[ETDRS\] level \> 20, by an ophthalmologist who was blinded to the proteomic displays of T2DM with and without complication \[[@CR12]\]. To derive a unique phenotype of T2DM with nephropathy or retinopathy for identifying its biomarkers, we studied the samples from T2DM with nephropathy at the AER \> 0.3 mg/mg in which those with co-morbidity of retinopathy (ETDRS \>20) were excluded, and studied the samples from T2DM with retinopathy (ETDRS \> 20) in which those with co-morbidity of nephropathy at AER \> 0.3 mg/mg were excluded.

Enrichment of low abundance plasma proteins {#Sec5}
-------------------------------------------

Plasma samples (50 ul) from 8 pairs of age-matched normal adults and T2DM patients were subject to the multiple affinity removal of 14 high abundance proteins (albumin, IgA, IgG, IgM, antitrypsin, Transferrin, haptoglobin, fibrinogen, alpha2-macroglobulin, alpha1-acid glycoprotein, apolipoproteinA1, ApolipoproteinA2, complement C3, transthyretin), purchased from Agilent Technologies (Santa Clara, CA). The low abundance proteins were harvested from the drop through phase \[[@CR13]\]. After protein measurement, plasma samples with 50 ug were loaded to gel electrophoresis followed by in-gel digestion for nano LC-ESI mass spectrometry.

SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and in-gel trypsin digestion for nano LC-ESI mass spectrometry {#Sec6}
----------------------------------------------------------------------------------------------------------------

We subjected the low abundance proteins (50 ug) of 8 pairs of plasma samples from normal adults and T2DM patients to SDS-PAGE. We then excised each gel into 16 parallel pieces for in-gel digestion with trypsin at 20 ug/ul. The trypsin-digested peptides were extracted twice with 1 % trifluoroacetic acid (TFA) in 100 % acetonitrile (ACN) and loaded into a nano LC-ESI mass spectrometry (Bruker-Franzen Analytik, Bremen, Germany). Mobile phase buffer was 20 % water + 80 % acetonitrile + 0.1 % formic acid at room temperature. Loading flow was 20 μL/min and flow rate was 300 nl/min. Silica-based reversed phase column C18 (PepMap 75 μm × 15 cm, 3 μm particle size, 100 Å pore size) was used. The autoproteolysis products of trypsin (m/z 842.51, 1045.56, 2211.10) were used as internal calibrates. The precision of molecular weight estimation was less than 0.5 Dalton. Identification of peptide and protein matches was performed using Mascot software (SWISS-Prot) \[[@CR14]\].

Validation of the protein concentrations of the 6 proteins higher differential displays in T2DM by enzyme-linked immunoassay (EIA) assay {#Sec7}
----------------------------------------------------------------------------------------------------------------------------------------

Plasma samples (50ul) with different dilutions as recommended by the manufacturers were added to 96-well EIA plates coated with mouse monoclonal antibodies (Abcam Inc., Cambridge, UK). The wells were incubated at 25 °C for 30 min. After washing twice, the secondary antibody of goat anti-mouse immunoglobulin antibody conjugated with horseradish peroxidase (HRP) (Santa Cruz Biotech. Inc., Santa Cruz, CA) was added to the reaction for 30 min. The reactions were visualized by OD550nm (Pierce, Rockford, IL) as previously described \[[@CR15]\]. Concentrations of plasma proteins were determined by the interpolation of a standard curve made from a series of well-known concentrations of standard samples \[[@CR15]\].

Statistical methods and data analysis {#Sec8}
-------------------------------------

The differentially displayed proteomes between 8 pairs of plasma samples from normal adults and T2DM patients were initially analyzed by MetaCore software for identifying functional pathways of the differential proteins displays. The sample sizes used to validate the differentially proteomic displays were set at ≧ 30, based on the effect size of 0.4 and power of 0.8. Statistics was analyzed by the Statistical Package for Social Sciences (SPSS Inc., Chicago) version 13.0 for Windows. The adjusted p values with multiple comparisons were corrected by Bonderroni correction.

Results {#Sec9}
=======

Demographic data of subjects providing blood samples for this study {#Sec10}
-------------------------------------------------------------------

Two different batches of plasma samples from normal adults and T2DM patients were studied. The first batch of plasma samples including 8 pairs of equal gender ratio (4:4) and age-matched plasma from normal adults and T2DM patients were subject to proteomic differential displays by enrichment of low abundance proteins followed by gel electrophoresis and nano LC/ESI spectrometric analyses. After the proteomic differential displays, we used another cohort of plasma samples including 30 from normal adults and 149 from T2DM patients \[[@CR11], [@CR12]\] for validation of the 6 proteins related to metabolism or inflammation which were higher in the T2DM patients in the differentially proteomic displays. The demographic data among the normal adults and T2DM patients with and without complications were not significantly different as shown in Table [1](#Tab1){ref-type="table"}.Table 1Demographic data of normal adults and T2DM patients without and with complicationsPhenotypesNumberMale/femaleAge, Mean (SD)Normal adults3018/1260.0 (2.75)T2DM, no complication5034/1660.7 (8.50)T2DM, nephropathy4930/1962.0 (10.5)T2DM, retinopathy5030/1961.6 (10.4)Gender ratios (Chi-square, *p* \> 0.05) and age distributions (student t, *p* \> 0.05) are not significant among groups

Proteomic differential displays of plasma between normal adults and T2DM patients {#Sec11}
---------------------------------------------------------------------------------

We found that the low abundance proteins enriched by the multiple affinity removal of 14 high abundance proteins showed no different bands of high abundance proteins. The low abundance proteins on the SDS-PAGE gels were incised into 16 pieces for in-gel digestion. Each fraction of in-gel digestion was subject to nano LC-ESI analyses of peptides fingerprints. Proteins identified in all 8 plasma samples of normal adults and T2DM patients were, respectively, listed and analyzed by MetaCore analysis. A total of 826 proteins in plasma were consistently identified from 8 plasma samples of normal adults, and 817 were consistently identified in 8 plasma samples of T2DM patients. In a cut-off of 2-fold higher or lower levels of proteins between controls and T2DM, we found that the levels of 563 proteins were not different between controls and T2DM patients. Of the 344 proteins with higher levels in controls, 121 were under-detectable in T2DM patients; and of the 340 proteins with higher in T2DM patients, 110 were under-detectable in normal adults. The differential displays of proteins could be classified into 5 functional pathways. They are receptor binding, protein binding, cytoskeletal protein binding, ATP binding and adenyl ribonucleotide binding proteins, in which the former 3 classes are higher in T2DM patients, and the latter 2 are lower in T2DM patients. One hundred and ten proteins identified in T2DM patients were undetectable in normal adults, and 121 proteins identified in normal adults were undetectable in T2DM patients (Table [2](#Tab2){ref-type="table"}). We chose to validate the 6 proteins: Dipeptidyl peptidase-4 (DPP4), prolactin-induced protein (PIP), neutrophil gelatinase-associated lipocalin (NGAL), L1 cell adhesion molecule (L1CAM), thrombospondin-2 (THBS2), and glucagon-like peptide 1 (GLP1), related to metabolism or inflammation, which could be validated by enzyme-linked immunoassay and were higher expression in T2DM patients, for differentiation between with and without complications in another cohort of population.Table 2The proteins identified in T2DM patients or normal adults were, respectively, under-detectable in normal adults or T2DM patientsDifferencesNo.Names of the proteins different between normal and T2DMT2DM \> Normal110ABCA7; ADCY5; ADCY5; AKD1; ALPK2; ANPRB; AP3D1; APOF; ARAP2; ARMC2; ARTN; BAZ1A; BOD1L; BRPF3; BSN; CAH14; L1CAM; CASC5; CASP5; CDHR1; CKAP5; CLCF1; CWC15; CXCL1(SDF1); DAZ2; DDX12; DDX42; DDX54; DGKZ; DIDO1; DLG1; DLGP5; DMXL2; DOCK2; DOCK3; DPP4; EDRF1; EIF3A; ELP2; EP400; EPHA8; ERBB4; ERC2; ERCC6; ERI2; EXPH5; EXTL3; EYS; FAS; FBN2; FGD2; FMN2; FOG2; FOLR2; FREM3; FYN; GMIP; GLP1; GPR98; GRIN1; GUC2D; GVIN1; HNRPM; HTRA2; IF6; ITAL; KALRN; KI67; KSR1; LAT2; LENG8; LETM1; MAST3; MBD4; MCM3; MCM5; MED1; MINT; MMP3; MRAP; MRCKB; MSH6; MUC2; MYH13; MYH4; MYH7; MYH9; MYO1A; MYOF; MYST4; NBEA; NBN; NCOA3; NFM; NGAL(LCN2); NMDZ1; NUMA1; PABP2; PARD3; PDE4A; PI4KA; PIP; RGS14; SHRM2; SPTA1; SPTA1; THBS2; TLN2; TPM4; USH2A.Normal \> T2DM121ABCA5; ACBG1; ACSA; ACSF4; ACTS; ADNP; AIFM2; AKAP6; AL1L1; AMPM1; ANGT I; ANGT II; ANGT III; AGNT IV; POC1; APOD; ASH1L; ASXL3; ATAD5; ATRX; BAI1; BDP1; BLVRB; BPNT1; BRE1A; CAPS1; CASP; CAYP1; CCDC6; CDC5L; CDKL5; CENPJ; CHD9; CNKR2; COTL1; CP110; CROCC; CRTAP; CTC1; CUX1; DDX11; AN; DDX24; DGKD; DGKQ; DHX36; DHX9; DIAP1; DNMT1; DSG1; DYN2; DZIP1; EIF3L; ELL; ELYS; EPIPL; ERF3B; EST1A; EVPL; FABD; FAK2; FANCM; FGD4; FGD6; FGFR1; FOXE1; FRYL; FUBP2; FYCO1; H4; HBG1; HBG2; HCK; HMGX3; IDH3A; KCNH5; KCNN2; KDM2B; KDM4A; KDM5B; KDM5D; KPCD1; KRT34; KRT81; KRT82; KRT85; LAMA3; LAMA4; LIMS1; LNX1; LRRK1; MACC1; MAP1A; MASP1; MED16; MLX; MPDZ; MTUS2; MYH14; MYH3; MYH6; MYO5B; MYRIP; NBR1; NCF2; NCK2; NF1; NIN; NIPBL; NOM1; NSF; ORC1; p110 CUX1; PANK2; PB1; PERF; PEX1; PTPRT; SHRM3; SOS2; TIAM2.

Validation of protein differential displays among T2DM patients with and without complications {#Sec12}
----------------------------------------------------------------------------------------------

Validation of the 6 proteins showing higher expression in T2DM patients on the protein differential displays was performed. We found that the plasma prolactin-induced protein (PIP) levels were higher in T2DM patients without complication (*p* = 0.020), particularly in T2DM patients with albuminuria (*p* = 0.010) (Table [3](#Tab3){ref-type="table"}). Interestingly, T2DM patients with retinopathy had no significant increase of PIP levels. We could not validate that GLP1 (Table [4](#Tab4){ref-type="table"}) and DPP4 (Table [5](#Tab5){ref-type="table"}) levels were different between T2DM patients and normal adults in the EIA assays. However, we did find that thrombospondin-2 (THBS2) levels were significantly higher in T2DM patients with nephropathy but not retinopathy (Table [6](#Tab6){ref-type="table"}). Results also showed that L1CAM levels were significantly higher in T2DM with retinopathy but not significantly higher in T2DM without or with nephropathy (Table [7](#Tab7){ref-type="table"}) than in normal adults. In contrast, NGAL levels were significantly higher in T2DM patients with nephropathy but not retinopathy (Table [8](#Tab8){ref-type="table"}).Table 3Plasma PIP levels among normal adults and T2DM patients with and without complicationsSubjects*nM (SD)p* valueNormal adults30249.61 (159.02)-T2DM, no complication50425.67 (473.29)0.020T2DM, nephropathy49534.32 (725.84)0.010\*T2DM, retinopathy50318.64 (459.78)0.430\**p* \< 0.013 were considered significant difference based on the null hypothesis of *p* \< 0.05 with Bonferroni correction Table 4Plasma GLP1 levels among normal adults and T2DM patients with and without complicationsSubjects*nM (SD)p* valueNormal adults3035.20 (12.47)-T2DM, no complication5044.54 (36.17)0.177T2DM, nephropathy4937.82 (27.73)0.627T2DM, retinopathy5032.39 (34.14)0.666 Table 5Plasma DPP4 levels among normal adults and T2DM patients with and without complicationsSubjects*nM (SD)p* valueNormal adults30168.44 (40.59)-T2DM, no complication50161.74 (50.97)0.540T2DM, nephropathy49162.13 (54.47)0.590T2DM, retinopathy50166.28 (41.83)0.370 Table 6Plasma THBS2 levels normal adults and T2DM patients with and without complicationsSubjects*nM (SD)p* valueNormal adults3016.05 (5.43)-T2DM, no complication5014.29 (7.85)0.285T2DM, nephropathy4929.96 (17.20)0.012\*T2DM, retinopathy5017.51 (14.93)0.532\**p* \< 0.013 were considered significant difference based on the null hypothesis of *p* \< 0.05 with Bonferroni correction Table 7Plasma L1CAM levels normal adults and T2DM patients with and without complicationsSubjects*nM (SD)p* valueNormal adults300.00 (undetectable)-T2DM, no complication501. 96 (6.41)0.195T2DM, nephropathy492.62 (7.50)0.018T2DM, retinopathy502.24 (6.04)0.012\*\**p* \< 0.013 were considered significant difference based on the null hypothesis of *p* \< 0.05 with Bonferroni correction Table 8Plasma NGAL levels among normal adults and T2DM patients with and without complicationsSubjects*nM (SD)p* valueNormal adults3065.93 (22.88)-T2DM, no complication5097.65 (31.70)0.000T2DM, nephropathy49161.87 (205.76)0.000T2DM, retinopathy5051.90 (44.15)0.111

Discussion {#Sec13}
==========

Using the tool of proteomic differential displays, we have identified that many plasma metabolic and inflammatory proteins such as THBS2, NGAL and PIP levels might be good biomarkers for the correlation to T2DM with nephropathy. Also, T2DM patients with retinopathy have normal THBS2, NGAL and PIP levels but elevated L1CAM levels. Whether these biomarkers could be used for early prediction of T2DM with different complications in these patients requires further prospective studies.

Neutrophil gelatinase-associated lipocalin (NGAL) also called LCN2 (Lipocalin-2) has been shown to be a biomarker for acute kidney injury \[[@CR16]\]. Recently, Lacquaniti, et al. \[[@CR17]\] also showed that normoalbuminuric diabetic nephropathy was associated with higher plasma NGAL levels. In this study, we have further shown that T2DM patients with nephropathy (AER \> 0.3 mg/mg) but not those with retinopathy (ETDRS \> 20) has a significantly higher plasma NGAL. We also found that the plasma prolactin-induced protein (PIP) levels were higher in T2DM patients with nephropathy. PIP has been implicated in immunosuppressive effects \[[@CR18]\]. This suggests that PIP may act an immunosuppressive biomarker for T2DM in response to microvascular inflammation in T2DM with nephropathy. The THBS2 levels were significantly higher in T2DM patients with nephropathy, but not significantly higher in T2DM patients with retinopathy. This is somewhat different from another report showing the overexpression of THBS2 in the vitreous body from patients with proliferative diabetic retinopathy \[[@CR19]\]. In THBS2 knockout mice, absence of THBS2 was related to anti-angiogenesis and prolonged inflammation \[[@CR20]\]. Taken together, these results suggest that certain blood inflammatory and angiogenic proteins may be involved in T2DM with nephropathy or retinopathy, and may be used as predictors of T2DM with nephropathy or retinopathy if further large-scale clinical investigations with longitudinal data validate the clinical relevance of these proteins as potential biomarkers.

Dipeptidyl peptidase-4 (DPP4) is an enzyme that could catabolize GLP1 and is implicated in T2DM patients with complication \[[@CR21]\]. In an animal study, Balkan et al. \[[@CR22]\] showed that inhibition of DPP4 increased plasma GLP1 concentrations and improved oral glucose tolerance. We had initially found that plasma DPP4 and GLP1 levels in mass spectrometric analyses were higher in 8 pairs of T2DM patients in comparison to those of normal adults. However, we found there was no significant difference in the validation by a quantitative enzyme-linked immunoassay with a larger population of 149 T2DM patients with nephropathy or retinopathy. This may be because the DPP4 and GLP1 are labile in the blood, or have different isoforms or metabolites not feasible for the measurement by enzyme-linked immunoassay.

Neural cell adhesion molecule, L1 (L1CAM) was found to be significantly higher in T2DM patients with retinopathy but not T2DM without or with nephropathy. L1CAM has been shown to induce FGF receptor-mediated neurite outgrowth \[[@CR23]\]. Recently, it was also shown to be a urinary biomarker in obstructive nephropathy \[[@CR24]\]. In blood, we are the first to show that a significantly higher L1CAM, but normal PIP, THBS2 or NGAL level was associated with retinopathy of T2DM.

The strength of this study is to deplete 14 high abundance proteins using an affinity removal system before a gel electrophoresis followed by nano LC-ESI mass spectrometry, and to validate the proteomic differentiation of T2DM patients with nephropathy or retinopathy by another cohort of 149 T2DM patients. There are also some limitations in this study. 1) Although we found 340 plasma proteins had higher levels in T2DM patients than controls, we just validated 6 of them related to metabolism or inflammation in a quantitative measurement due to limited availability of quantitative measurement of blood proteins identified in the proteomic differential displays. 2) Since this study is done in a single population recruited from a medical center, the results from this study may need further validation from other ethnic populations. 3) The quantitative validation of plasma biomarkers in the study is separately performed in an EIA. Recently, there are new complementary approaches for the mass spectrometry of high-throughput monitoring of protein modifications and the absolute quantification of proteins in a picomolar range \[[@CR25]\].

Conclusions {#Sec14}
===========

We used nano LC-ESI mass spectrometry with in-gel digestion after a gel electrophoresis for analyses of differential displays on plasma low abundance proteins between T2DM patients with and without complications, and found certain proteins were suitable for differentiation of T2DM patients with and without complications. THBS2, NGAL and PIP levels might be good biomarkers for the association of T2DM with nephropathy. Also, T2DM patients with retinopathy have normal THBS2, NGAL and PIP levels but a significantly higher L1CAM level. Further prospective studies to validate these proteins with and without modifications suitable for the prediction of T2DM patients with nephropathy or retinopathy are required.
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